Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Tebentafusp |
Trade Name | Kimmtrak |
Synonyms | ImmTAC-gp100|Tebentafusp-tebn|IMCgp100 |
Drug Descriptions |
Kimmtrak (tebentafusp) is a gp100 antigen-specific human T-cell receptor (TCR) linked to an anti-CD3 antibody fragment, which activates cytotoxic immune response against gp100-expressing tumor cells (PMID: 24531387, PMID: 31336704, PMID: 32816891). Kimmtrak (tebentafusp) is FDA approved for use in HLA-A*2:01-positive metastatic or unresectable uveal melanoma patients. |
DrugClasses | |
CAS Registry Number | 1874157-95-5 |
NCIT ID | C94208 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Carmustine + Tebentafusp | Carmustine Tebentafusp | 0 | 1 |
Pembrolizumab + Tebentafusp | Pembrolizumab Tebentafusp | 0 | 1 |
Sargramostim + Tebentafusp | Sargramostim Tebentafusp | 0 | 1 |
Tebentafusp | Tebentafusp | 0 | 10 |